Therapeutic or Preventive Procedure – Page 112

Diagonal Therapeutics Secures $128 Million Series A Funding through Innovative Antibody Agonists

2 years ago talkbio0Tagged Antibody agonism, Cells, Diagonal, Funding, Rare Diseases, switches

Diagonal Therapeutics, Series A funding, Antibody agonism, Cellular “on” switches, Rare diseases

Diagonal Therapeutics Secures $128 Million Funding to Target Rare Diseases

2 years ago talkbio0Tagged Antibodies, Blue-chip, Chronic anemia, Diagonal, Merck's, Orphan disease treatment, Rare diseases focus, research, Winrevair

Diagonal Therapeutics, Antibody biotech, $128 million funding, Rare diseases focus, Orphan disease treatment, Chronic anemia, Merck’s Winrevair related research, Blue-chip investors

Roivant’s Anti-Inflammatory Med Shows Promise in Phase 2 Trial for Non-Anterior Non-Infectious Uveitis

2 years ago talkbio0Tagged Brepocitinib, Humira comparison, NIU, Non-Anterior Non-Infectious Uveitis, Pharma stake acquisition, Priovant, Roivant, Stock buyback plan, Sumitomo

Roivant, Brepocitinib, Phase 2 trial success, Non-Anterior Non-Infectious Uveitis (NIU), Priovant Therapeutics, Stock buyback plan, Sumitomo Pharma stake acquisition, Humira comparison

Acorda Therapeutics Concludes $185M Asset Sale with Merz amid Bankruptcy Filing Following Disappointing Sales

2 years ago talkbio0Tagged Acorda, asset, Bankruptcy filing, Biogen returns, Declining sales, ex-US, Fampyra, Generic competition, Merz, Multiple Sclerosis drug, Neurological diseases, year

Acorda Therapeutics, $185M asset sale, Merz, Bankruptcy filing, Years of disappointing sales, Multiple Sclerosis drug Fampyra, Biogen returns ex-US rights, Generic competition, Declining sales, Neurological diseases

Verve Temporarily Halts Lead Base Editing Study Following Adverse Event, Prioritizes Alternative Therapy

2 years ago talkbio0Tagged Adverse event, Alanine Transaminase, Alternative Therapies, Cognitive function: initiation, Elevation procedure, Grade three rank, Heart-1 study, Heart-2 clinical trial, Ionizable, Lead base editing program, lipid delivery system, Pause enrollment, Phase Ib Heart-2 clinical trial, Q2 2024, SAEs, Serious adverse events, Thrombocytopenia, VERVE-101, VERVE-102

Verve Therapeutics, Lead base editing program, Adverse event, VERVE-101, Serious adverse events (SAEs), Grade 3 ALT elevation, Thrombocytopenia, Pause enrollment in Heart-1 study, Alternative therapy focus: VERVE-102, Ionizable lipid delivery system, Phase Ib Heart-2 clinical trial, Q2 2024 initiation of Heart-2 clinical trial.

Carisma Therapeutics to Lay Off Staff, Discontinue CAR-M Programs in Pursuit of Second Candidate

2 years ago talkbio0Tagged 37%, anti-HER2, Anti-mesothelin, Autologous Anti-HER2 CAR Macrophages CT-0508, CAR-macrophage, CAR-monocyte, Carisma, clinical CAR-M program, CT-1119, Dropping, layoffs, second, Workforce reduction

Carisma Therapeutics, Layoffs, Workforce reduction (37%), Dropping clinical CAR-M program, Anti-HER2 CAR-macrophage CT-0508, Anti-mesothelin CAR-monocyte candidate CT-1119, Second candidate focus

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

2 years ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data

Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment

2 years ago talkbio0Tagged Anemia, Sickle Cell, ClinicalTrials.gov, Grail, inclacumab, Pfizer, Phase 3 Clinical Trials, Poor Accrual, Recruitment Challenges, THRIVE Program

Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies

Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

2 years ago talkbio0Tagged Antisense Oligonucleotides, Genetic Epilepsy Drug, Infantile Severe Myoclonic Epilepsy, investor, Level of interest, Positive Clinical Trial, Seizures, STK-001, Stoke

Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm

Axsome Therapeutics’ Small Molecule AXS-12 Successful in Phase III Narcolepsy Trial

2 years ago talkbio0Tagged AXS-12, Axsome, Cataplexy, Drowsiness, Improved, memory/, Narcolepsy, Phase 3 Clinical Trials, reboxetine, safety profile, Severities

Axsome Therapeutics, AXS-12 (reboxetine), Phase III trial, Narcolepsy, Cataplexy reduction, Improved cognition/ memory/ sleepiness severity, Safety profile